Officer sold
Incyte's Principal Accounting Officer sold $59K of Incyte shares. Nobody planned it ahead of time.
Loading…
Traded Nov 21, 2025 · Filed Nov 25, 2025
Incyte's Principal Accounting Officer sold $17K of Incyte shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$17,238
Shares × reported transaction price
24 days after results of Oct 28, 2025, 81 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $102.06 on Nov 21, 2025, 85% above its 52-week low and 6% below its high, after a 22% rise over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 88% of the way up, from 250 adjusted closes. 30 trading days earlier: $83.80 on Oct 10, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, 26 days after this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -3.9% | +0.6% | -4.5% |
| 30 days | -5.2% | +1.6% | -6.8% |
| 90 days | -4.3% | +1.1% | -5.5% |
| 180 days | -8.1% | +10.4% | -18.5% |
Past results only. Not a forecast.
Incyte's Principal Accounting Officer sold $59K of Incyte shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.